CSF3 and breast carcinoma: Our findings conflict with a recent report from Botswana, which found that 26 patients with breast cancer living with HIV experienced significantly lower neoadjuvant chemotherapy RDI than 84 patients without HIV (mean RDI: 0.70 vs. 0.81).21 However, that study also found comparable rates of myelotoxicity and reported that granulocyte colony-­stimulating factor was not typically used.